We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche's (RHHBY) Tecentriq Disappoints in Ovarian Cancer Study
Read MoreHide Full Article
Roche Holdings (RHHBY - Free Report) announced disappointing results from a late-stage study on immune-oncology drug, Tecentriq, for the indication of ovarian cancer.
The phase III IMagyn050 study showed that the addition of Tecentriq to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced-stage ovarian cancer.
Nevertheless, data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis.
Positive results from the study would have supported a potential approval of the combination in this indication, which is the 8th most commonly occurring cancer in women worldwide, with nearly 300,000 new cases diagnosed each year.
Tecentriq sales came in at CHF644 million in the first quarter. Meanwhile, Roche is also evaluating the drug in multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. These include studies evaluating the drug both alone and in combination with other drugs.
However, the drug faces stiff competition from Merck’s (MRK - Free Report) Keytruda and Bristol-Myers’ (BMY - Free Report) Opdivo. Other PD-L1 inhibitors available in the market include AstraZeneca’s (AZN - Free Report) Imfinzi.
Roche’s stock has gained 10.8% in the year so far against the industry’s decline of 0.5%.
Separately, the company announced results from the second interim analysis of the phase IIIb STASEY study, which reinforces the safety profile of hemophilia drug, Hemlibra (emicizumab). STASEY is a single-arm, multicenter, open-label, phase IIIb clinical study where patients received Hemlibra for an average of 50.9 weeks.
Hemlibra is already approved to treat patients with hemophilia A with factor VIII inhibitors and those without factor VIII inhibitors in more than 70 countries worldwide, including the United States, the EU and Japan.
The results show that Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors. The data reinforce the safety profile of Hemlibra as characterized in the phase III HAVEN clinical program.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Roche's (RHHBY) Tecentriq Disappoints in Ovarian Cancer Study
Roche Holdings (RHHBY - Free Report) announced disappointing results from a late-stage study on immune-oncology drug, Tecentriq, for the indication of ovarian cancer.
The phase III IMagyn050 study showed that the addition of Tecentriq to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced-stage ovarian cancer.
Nevertheless, data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis.
Positive results from the study would have supported a potential approval of the combination in this indication, which is the 8th most commonly occurring cancer in women worldwide, with nearly 300,000 new cases diagnosed each year.
Tecentriq sales came in at CHF644 million in the first quarter. Meanwhile, Roche is also evaluating the drug in multiple ongoing and planned phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. These include studies evaluating the drug both alone and in combination with other drugs.
However, the drug faces stiff competition from Merck’s (MRK - Free Report) Keytruda and Bristol-Myers’ (BMY - Free Report) Opdivo. Other PD-L1 inhibitors available in the market include AstraZeneca’s (AZN - Free Report) Imfinzi.
Roche’s stock has gained 10.8% in the year so far against the industry’s decline of 0.5%.
Separately, the company announced results from the second interim analysis of the phase IIIb STASEY study, which reinforces the safety profile of hemophilia drug, Hemlibra (emicizumab). STASEY is a single-arm, multicenter, open-label, phase IIIb clinical study where patients received Hemlibra for an average of 50.9 weeks.
Hemlibra is already approved to treat patients with hemophilia A with factor VIII inhibitors and those without factor VIII inhibitors in more than 70 countries worldwide, including the United States, the EU and Japan.
The results show that Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors. The data reinforce the safety profile of Hemlibra as characterized in the phase III HAVEN clinical program.
Roche currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>